IRIS
DE LUCA, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.035
AS - Asia 3.079
EU - Europa 2.826
SA - Sud America 360
Continente sconosciuto - Info sul continente non disponibili 155
AF - Africa 50
OC - Oceania 2
Totale 11.507
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.930
SG - Singapore 1.194
CN - Cina 861
UA - Ucraina 458
IE - Irlanda 438
GB - Regno Unito 370
TR - Turchia 347
RU - Federazione Russa 319
VN - Vietnam 304
SE - Svezia 289
BR - Brasile 286
IT - Italia 258
DE - Germania 231
FR - Francia 210
FI - Finlandia 131
IN - India 131
CA - Canada 58
BD - Bangladesh 51
HK - Hong Kong 33
AR - Argentina 27
JP - Giappone 27
MX - Messico 24
PL - Polonia 23
IQ - Iraq 19
KR - Corea 18
ZA - Sudafrica 18
CZ - Repubblica Ceca 17
ID - Indonesia 16
ES - Italia 15
EC - Ecuador 13
NL - Olanda 13
CL - Cile 12
CH - Svizzera 10
IR - Iran 10
JM - Giamaica 10
BE - Belgio 9
EU - Europa 9
LT - Lituania 9
AE - Emirati Arabi Uniti 8
CO - Colombia 8
MA - Marocco 8
IL - Israele 7
SA - Arabia Saudita 7
UZ - Uzbekistan 7
AT - Austria 6
KE - Kenya 6
PK - Pakistan 6
RS - Serbia 6
TN - Tunisia 6
KZ - Kazakistan 5
NP - Nepal 5
VE - Venezuela 5
EG - Egitto 4
ET - Etiopia 4
GR - Grecia 4
JO - Giordania 4
UY - Uruguay 4
AZ - Azerbaigian 3
NI - Nicaragua 3
AM - Armenia 2
AU - Australia 2
BG - Bulgaria 2
BH - Bahrain 2
CR - Costa Rica 2
HN - Honduras 2
MK - Macedonia 2
MY - Malesia 2
PE - Perù 2
PH - Filippine 2
PR - Porto Rico 2
RO - Romania 2
SY - Repubblica araba siriana 2
AL - Albania 1
BW - Botswana 1
BZ - Belize 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GY - Guiana 1
HT - Haiti 1
IM - Isola di Man 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
LY - Libia 1
MN - Mongolia 1
NG - Nigeria 1
PY - Paraguay 1
SR - Suriname 1
TJ - Tagikistan 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 11.362
Salva come PNG Salva come JPEG
Città #
Singapore 882
San Jose 528
Jacksonville 511
Chandler 508
Dublin 433
Dallas 358
Ashburn 317
Southend 258
Council Bluffs 243
Beijing 223
Izmir 192
Princeton 188
Nanjing 152
Wilmington 130
Los Angeles 117
Santa Clara 116
The Dalles 100
Ho Chi Minh City 89
New York 88
Cambridge 84
Dearborn 84
Hanoi 62
Munich 61
Tongling 59
Nanchang 58
Woodbridge 52
Ann Arbor 51
Altamura 45
Buffalo 42
Moscow 41
Chieti 35
Dong Ket 33
Houston 32
Columbus 31
São Paulo 31
Hefei 30
Hong Kong 29
Jiaxing 29
Helsinki 27
Montreal 27
Redondo Beach 26
Boardman 25
Norwalk 25
Shenyang 25
Frankfurt am Main 23
Tokyo 23
Tianjin 20
Turku 20
Brooklyn 19
Grevenbroich 19
Kunming 19
Warsaw 19
London 18
Orem 18
Phoenix 17
Seoul 17
Washington 17
Atlanta 16
Denver 16
Hebei 16
Da Nang 15
Mexico City 15
Stockholm 15
Johannesburg 14
Toronto 14
San Francisco 13
Brno 12
Changsha 12
Chicago 12
Hangzhou 12
Leawood 12
San Mateo 12
Chennai 11
Rome 11
Ardabil 10
Baghdad 10
Nuremberg 10
Poplar 10
Rio de Janeiro 10
Augusta 9
Cedar Knolls 9
Haiphong 9
Jinan 9
Mumbai 9
Torino 9
Amsterdam 8
Biên Hòa 8
Boston 8
Brussels 8
Guangzhou 8
Lanzhou 8
Manchester 8
Pescara 8
Teramo 8
Campobasso 7
Can Tho 7
Charlotte 7
Monmouth Junction 7
Tashkent 7
Ankara 6
Totale 7.171
Salva come PNG Salva come JPEG
Nome #
Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid 194
Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells 181
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 171
IL 13 in multiple sclerosis 170
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 166
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 165
Increasing age at disability milestones among MS patients in the MSBase Registry 154
Dysimmune demyelinating polyneuropathies: expression of adhesion molecules in sural nerves and changes in cellular immunity (suppressor cell function and cytokine mRNA expression) induced by treatment (progetto presentato a Telethon) 153
Acetylcholine in multiple sclerosis: possible involvement in the modulation of the immune response and in oligodendrocyte recruitment. 152
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 151
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 149
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 148
Anti-glycolipid and anti-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy 145
Interferon β1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis 144
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 143
Contribution of metabolomics to multiple sclerosis diagnosis, prognosis and treatment 143
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 141
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 140
Effect of TNF intraneural injection into the rat sciatic nerve 139
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 139
Chemokine production by mononuclear cells from relapsing-remitting multiple sclerosis (RR-MS) patients 139
La funzione soppressoria è ridotta nella polineuropatia demielinizzante cronica infiammatoria (CIDP) 138
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 137
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 135
Rantes Levels and mRNA Expression in Relapsing-Remitting Multiple Sclerosis (RR-MS): Effect of interferon Beta 1b (IFNBeta 1b) Treatment 134
Effect of rhTNF-alpha injection into rat sciatic nerve 132
CD1A and CD1E gene polymorphisms are associated withsusceptibility to multiple sclerosis 131
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 131
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 128
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 128
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 127
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 127
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 126
Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. 126
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. 125
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 125
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 124
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 124
JCV-Ab serostatus in MS patients treated with Natalizumab 124
Effects of IL10 on recombinant interferon-beta1b stimulated suppressor cell function in MS and controls subjects 122
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 121
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 121
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 121
Effect of rhTNF-a injection into rat sciatic nerve 120
Nail loss after teriflunomide treatment: a new potential adverse event 120
rlFN-beta-1B stimulated suppressor cell function in multiple sclerosis: effects of anti-IL-10 monoclonal antibody 119
Rantes and MCP-1 Secretion by Mononuclear Cells of Patients with Nultiple Sclerosis 119
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 119
Serum soluble adhesion molecules and proinflammatory cytokines are not increased in chronic inflammatory demyelinating polyneuropathy 116
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 116
Interferon beta normalizes suppressor cell function in dysimmune neuropathies. 116
Interferon beta1b: the Chieti experience 115
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases 115
Shared T Cell Receptor Usage of Cerebrospinal Fluid Cells in Familial Multiple Sclerosis da: X° National A.I.N.I. Congress Association Italiana Neuroimmunologia - Florence, Italy, November 15/16,1999 111
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 111
A Multicentre italian study on efficacy and safety of Glatiramer Acetate in multiple sclerosis patients with allergic respiratory diseases 111
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 110
Proteomic investigations on differential post-translational modification of transthyretin in multiple sclerosis. 110
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 108
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 107
Mononeuropathy following subcutaneous interferon-β injection 106
Suppressor cell function is decreased in chronic inflammatory demyelinating polyneuropathy 105
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 104
Livelli sierici e liquorali di IL13 nella Sclerosi Multipla 103
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 101
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients 100
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 100
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 100
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 99
Effects of IFN-Beta on rantes and MCP-1 secretion by mononuclear cells frm patients with multiple sclerosis 99
Epilepsy and multiple sclerosis: Clinical, radiological, electrophysiological and neuropsychological aspects 98
Interferon β 1b: The Chieti experience 98
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 98
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. 96
Pregnancy and fetal outcomes after paternal exposure to disease modifying drugs for multiple sclerosis 96
IL-13 levels in serum and cerebro-spinal fluid of multiple sclerosis patients 95
Evaluation of suppressor cell function in chronicn inflammatory demyelinating polyneuropathy (CIDP) 95
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 94
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 94
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 93
Interferone beta1b: bilancio su un gruppo di 30 pazienti 92
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 89
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose 88
Pregnancy And Fetal Outcomes After Paternal Exposure To Disease Modifying Drugs For Multiple Sclerosis (P4.157) 88
Non-neuronal acetylcholine: a new modulator of immune responses in multiple sclerosis patients. 87
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 87
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. 86
Modulation of the immune response in multiple sclerosis patients: effect of non-neuronal acetylcholine 86
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 86
Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge 85
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 84
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 82
Efficacy and safety of glatiramer acetate in multiple sclerosis patients with allergicrespiratory diseases. 82
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 81
Gestione degli effetti indesiderati della terapia con interferone beta nella sclerosi multipla 80
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 79
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 72
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod 35
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 33
Epilepsy in MS and its association with cognitive and psychological burden 18
Totale 11.471
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.547
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.547
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022351 0 0 6 57 11 11 16 34 32 7 54 123
2022/20231.321 104 152 72 158 143 272 81 93 171 17 29 29
2023/2024653 46 30 38 16 37 225 145 30 0 31 5 50
2024/20251.766 117 317 334 26 34 65 42 59 123 94 230 325
2025/20263.785 334 144 500 492 363 204 598 189 391 283 201 86
2026/2027322 61 206 55 0 0 0 0 0 0 0 0 0
Totale 11.507